Clinical Trial Update: Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices [Phase 4]

View source ↗

Summary

Phase 4 trial comparing 24-hour versus 72-hour octreotide infusion to prevent early rebleeding from esophageal varices in patients with liver cirrhosis; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Variceal Bleeding
• Liver Cirrhosis
• Upper Gastrointestinal Bleeding

Drugs mentioned

• Sandostatin (Octreotide acetate)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Esophageal Varices, Liver Cirrhoses | Phase 4 | Status: TERMINATED | Results posted: 2025-11-20